Amneal Wins FDA Approval for Ready-to-Use Romidepsin Injection – No Mixing Needed!
FDA approves Amneal ready-to-use romidepsin injection for rare skin cancer, simplifying use and giving 180-day exclusivity.
/ 352 items
#XY Event-Driven Stocks↓
Alnylam Teams Up with ChatGPT Creator’s AI Company to Revolutionize RNAi Therapeutics
Alnylam Pharmaceuticals partners with AI startup Inceptive in a deal worth up to $2 billion to accelerate discovery of next-generation RNAi therapeutics using powerful AI models.
Lilly and Ascidian Sign $1.9B Deal to Bring RNA Gene Editing to Genetic Kidney Diseases
Eli Lilly teams with Ascidian to use RNA editing to treat rare kidney diseases without changing DNA.
ADC Therapeutics Stock Falls as Safety Worries Overshadow Strong ZYNLONTA Trial Results
ADC Therapeutics fell by nearly half after ZYNLONTA showed better cancer control but higher rates of serious side effects and deaths.
FDA Fast-Tracks Verastem’s Breakthrough Oral Drug for KRAS G12D Lung Cancer
Verastem’s VS-7375 pill targets KRAS G12D lung cancer, a rare, hard-to-treat mutation with no approved drugs yet.
Mineralys Therapeutics Raises $650M+ in Capital Blitz to Clear Path for Lorundrostat Launch
Mineralys raised cash via $150M stock sale, $500M loan, and $200M royalty buyout to fund drug ahead of FDA decision; stock fell.